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An  important aspect  of endemic-epidemic  disease  is  the  survival  of  the 
infectious  agent, particularly during the endemic periods  when much of the 
herd is  "immune."  Somehow or other the unwarranted assumption that the 
"immune"  state of the host precludes  survival of the infectious  agent has 
gained wide acceptance  even  though Obermeier,  in one of the first studies 
which  clearly associated  microbes  with the etiology  of an infectious disease, 
found that the spirochetes disappear from the blood during recovery from the 
first attack of relapsing  fever and return with  the relapse  (1);  the mecha- 
nism of that seeming anomaly was established  by Levaditi and Roch6 who 
showed  that  the  disappearance  was  associated  with  appearance  of  anti- 
bodies  which  were  effective against the spirochetes  which  evoked  the anti- 
bodies  but  not against those of the relapse  (2),  and  by Cunningham who 
showed  that the change  was one of antigenic variation, probably of genetic 
origin  (3). One may suspect  that the phenomenon  is a  general one, and one 
of basic biological significance. 
In the case of influenza, certainly, it may be reasoned, from available data, 
that a somewhat similar mechanism may be involved in survival of the virus: 
for instance, antigenic variation under the impetus of the changing immuno- 
logical constitution of the herd may account for the observations  that the 
succession  of outbreaks  of clinical  influenza  during  the  past  20  years  has 
been associated  with a  succession of strains of virus,  each of which included 
characterizing  antigenic complexes which  differed  from complexes  included 
in known antecedent strains (4, 5).  Two groups of data support the concept 
of variation (or mutation) of the influenza virus under the influence of im- 
posed  immunological  environments: Archetti and Horsfall (6)  obtained evi- 
dence of antigenic variation on passage  in embryonated eggs, of virus which 
had  been  partially neutralized by heterologous  antiserum; and  Isaacs  and 
Andrewes  (7), in somewhat similar experiments  with homologous antiserums, 
* Although this work received no direct support, it is a pleasure to acknowledge  the in- 
direct support derived from previous related studies under the Commission on Influenza, 
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obtained  variants,  which  in  their  opinion,  were  of  the  P-Q  (8)  kind.  The 
experiments  reported  in  the  present  paper  provide  more  direct  evidence. 
Virus  was  passaged,  serially,  by  intranasal  inoculation  of  groups  of  mice 
which  had  been  vaccinated  with  the  strictly  homologous  parent  strain  of 
virus; during propagation,  under those  imposed conditions, variants emerged 
which differed from the parent strain in antigenic characteristics. 
Materials and Methods 
Strain, of Virus.--The  A/Berkeley-I/53 strain of virus isolated by Dr.  E. H. Lennette 
during the  1952-53  outbreak of influenza in Berkeley was selected  as the parent passage 
strain because tests in this laboratory indicated that of the strains available, it was the most 
distantly removed from earlier strains. Other strains employed in the experiments included: 
A/England-I/51, A/England-I/54, A/Stockholm-I/54 (obtained from Dr.  C. H. Andrewes 
and  Dr.  Alick  Isaaes);  A/Albany-9/51  (Dr.  Irving  Gordon);  A/Kentucky-301/53  and 
A/Puerto Rico-301/54 (Dr. Manrice R. Hilleman); A/Ohio-I/53 (Dr. George  R. Anderson); 
A/New York-i/53  (Dr.  Frank L. Horsfall); A/Berkeley-2/53 (Dr.  E. H.  Lennette); and 
A/Chile-i/53 (Dr. Federico Ch£vez): the place and year of isolation are indicated in each 
instance by the strain identification. 
Vavcines.--All vaccines were  prepared  from  partially purified  virus  preparations,  in- 
activated with 1/4000 or 1/8000 formalin.  1 Allantoic fluids from eggs 12 to 14 days old which 
had been inoculated amuiotically 2 or 3 days previously were clarified in an ordinary centri- 
fuge at 4000 g.p.x~, for 30 minutes; the virus then was sedimentated at 40,000 (105 X gravity) 
for 60 minutes, and the sediment suspended to one-fifth or one-tenth of the original volume 
in pH 7.2, x¢/15 phosphate buffer.  Unsuspended particles were removed by centrifugation 
at 4,000 R.p.x~. for 30 minutes. Formalin then was added.  After 2 hours  at 37°C.  and 24 
hours or 48 hours in the refrigerator  (4°C.),  the formalinized suspensions were  tested for 
egg infectivity. None of the preparations contained detectable egg infectious material. 
Antiserums.--All antiserums were prepared by intraperitoneal inoculation of virus which 
had been partially purified; in most instances, the partial purification was achieved by cen- 
trifugation, as described  above. In the case of rabbits, three inoculations, each of 5 ml. of 
the resuspended virus, were  made at weekly intervals, and the animals bled 1 week  after 
the third inoculation. 
Except when indicated, the antiserums were deprived of  the normally present hemag- 
glutination-inhibitory substances by pepsin digestion followed  by fractional separation of 
the globulins, by slight modification of the method reported by Glanbiger for the partial 
purification of diphtheria and tetanus antitoxins (9). 
Mouse Passage.--Mice were inoculated intranasally while under ether anesthesia. The 
initial inoculation was  made with  Berkeley-I/53 infected  allantoic fluid; subinoculations 
were made with 10 per cent suspensions of pooled lungs from mice of the previous passage. 
In three instances, indicated in the text and tables, passage was made with allantoic fluid 
from eggs which had been inoculated with 10 per cent mouse lung suspension containing 
sufficient penicillin to provide 500 units per egg. The 10 per cent mouse lung suspensions 
were prepared in distilled water by grinding the lungs, aseptically, in a mortar, using alundum 
as an abrasive. Because of the time required for vaccination, most of the mice were relatively 
1 1/4000  formalin inactivated influenza virus readily, but also caused slow deterioration 
of  the  vaccines; consequently, later  vaccines were  inactivated with  the  greater  dilution 
(1/8000).  Since the  completion of the  reported  experiments,  1/10,000 formalin has  been 
found to be superior for the partially purified  virus suspensions. rao~s  P. ~GmL  281 
large (15 to 20 gin.) at the time of intranasal  inoculation. That situation  was not entirely 
an unfavorable  one because it permitted  inocula in excess of 0.1 ml.; the mice were anes- 
thetized and inoculated a second, and occasionally a third time in order to instill that volume 
of lung suspension. 
Egg  Infectivity  Tests.--Embryonated  eggs, 10  or  11  days old, were prepared  24 hours 
previous  to inoculation  by removing the shell and shell membrane  from the "butt" end; 
the open end of the egg was covered with a glass staining dish, and the eggs incubated.  The 
following morning eggs containing  embryos which did not survive  the manipulation  were 
discarded. Titrations  were made in tenfold steps,  each dilution being tested  in eight eggs. 
All inoculations, each of 0.25 ml., were made with 1~ inch, 23-gauge needles directly into 
the amniotic fluid: the same 1 mi. tuberculin  syringe was employed for the eight inocula- 
tions of the same dilution, but the needle was changed after four eggs had been inoculated. 
The culture  broth used to make the dilutions contained  sufficient penicillin to provide for 
500 units in each 0.25 ml. inoculum. 
Hcmagglutination-Inhibition  Tests.--The  antiserums  were  employed  in  a  single final 
dilution of 1:75 versus 6 serial threefold dilutions of allantoic fluid from eggs infected with 
the respective strain.  The test mixtures consisted of equal  volumes (0.2 mi.) of the 1:25 
antiserum,  virus dilution, and ~  per cent suspension of chicken erythrocytes.  After 1 hour 
at room temperature,  hemagglutination  was read as complete (++), partial  (+), or nega- 
tive (0), on the basis of pattern. 
EXPEI~  rM~.NTAL 
The  plan  of  the  experiment  was  to  passage  virus,  intranasally,  in  mice 
which had  been  "immunized"  by intraperitoneal  inoculation  of formaliniz~l 
homologous virus, the passage series to be initiated  in mice with "immunity" 
of relatively low degree and passage to be continued in mice with "immunity" 
of increasing  degree.  In order to free the variants which might be recovered, 
from the  taint  that they may have been the result  of laboratory contamina- 
tion,  the  experiments  not  only  were  performed  with  utmost  precautions, 
but  were made  with  one of the most recently isolated  strains  available,  and 
were so designed that the variants  obtained would be "new" and thus differ- 
ent from all previously known strains. 
Data  concerning  vaccination  and  passage  are  summarized  in  Table  I: 
with regard to vaccination, Table I  includes data dealing with strain of virus 
employed,  hemagglutinating  titer  of the  formalinized  vaccine,  and  quantity 
of vaccine  inoculated  intraperitoneally;  the  passage  data  (Table  I)  include 
number  of  elapsed  days  between  vaccination  and  intranasal  inoculation, 
average weight of the mice at the time of inoculation, and the egg infectivity 
titer  of  the  material  inoculated.  Also  shown,  are  the  degree  of pulmonary 
consolidation  and  the  elapsed  number  of  days  between  intranasal  inocula- 
tion and  the  killing  of the  mice.  Not shown in  Table  I  are  the  passages  in 
which  lung  suspensions  were  negative  for  egg  infectious  virus.  There  were 
three  such breaks in the series,  and each is indicated in Table I  by inclusion 
of the term "allantoic fluid" in the column headed Material  inoculated. 
As shown in Table I, the first passage was made in mice of approximately 20 tim. average 
weight and which had received, intraperitoncally,  a single inoculum of form~llni~l homolo- TABLE I 
Summary of Vacdnation  and Passage Data 
Vaccination  I  Passage 
d  , 
Berk-l/53 
~c 
log  ml.  days  gin.  log  days 
Allsntoic fluid 
2.9  0.25  3  20  Berk-!/53  9.0-[-  3, 3, 2 
0.25  5  20  I MV-I  --  0, 0, 0 







Aliantoic  fluid 
0.25  3NI  20  MV2EI 
0.25  5  20  MV2-M1 
0.25  7  20  MV2-M2 
0.25  9  20  MV2-M3 





0.25  14  20  MV2-M5 
0.25  2 
0.5  8N  16  MV2-M6 
0.5  5 
0.5  10  16  ! MV2-M7 
0.5  7 
Berk-t/53  2.9  0.5  9N  18!  MV2-M8 
Engl-1/51  2.9  0.5  2 
Berk-1/53  0.5  12  20  MV2-M9 
Engl-1/SI  0.5  5 
Berk-1/53  0.5  14  20  MV2-M10 
Engl-1/51  0.5  7 
Berk-1/53  0.5  16  22  MV2-M!I 









21  " 
22 
tc 
23  " 
2  MV1 
2  MV2 
10.0  3, 2, 2  2  MV2-MI 
4.6  0, 0, 0, 0  2  MV2-M2 
5.2  0, 0, 0, 0  3  MV2-M3 
5.1  0, 0, 0, 2  3  MV2-M4 
5.9  0, 0, 0, 3  2  MV2-M5 
5.2  2, +,  +,  0  2  MV2-M6 
4.7  2, +,  0, 0  2  MV2-M7 
5.1  2, 2, 0, 0,  2  MV2-M8 
5.8  2, +,  -t-, 01  3  MV2-M9 
4.1  2, 2, 0, 0  2  MV2-MI0 
4.4  2, 3, 0, 0  2  MV2-Mll 
5.4  0, 0, 0, 0  4  MV2-MI2 
Allantoic fluid 
Engl-1/51]  0.5  12N  16  MV2-M12E1  8.5  4, 3, + 
Berk.1/53~pool  2.9  0.5  10 
/ 
Engl-I/54J 
"  "  0.5  14  MV2-MI2-M!  3.5  2, 0 
"  "  0.5  12 
Aliantoic fluid 
"  0.5  12N  16  MV2-M12-M2, El  8.0  4, 3, 2 
"  0.5  5 
"  0.5  14  MV2-MI2-M2-M1  4.9  2, O, 0 
"  0.5  7 
"  0.5  16  22  MV2-M12-M2-M2  5.8  O, O, 2 
"  0.5  9 
"  0.5  3N  10  MV2-M12-M2-M3  5.2  0, 0, 0 
"  0.5  5  12  MV2-M12-M2-M4  6.1  +,  +,  0 
"  0.5  7  12  MV2-MI2-M2-M5  5.5  +,  +,  2 
"  0.5  2 
"  0.5  10  14  MV2-M12-M2-M6  4.9  2, +,  0 
"  0.5  5 
(MV2-M12-M2-  5.0  +,  +,  0 
M7 
2  MV2-MI2-MI 
2  MV2-MI2-M2 
2  MV2-M12-M2-M1 
2  MV2-M12-M2-M2 
3  MV2-M12-M2-M3 
2  MV2-MI2-M2-M4 
2  MV2-MI2-M2-M5 
3  MV2-M12-M2-M6 
2  MV2-M12-M2-M7 
* Tlter of formalinized vaccine. 
4, complete consolidation;  0, no gross lesions; 3, 2, +,  intermediate lesions. 
§ Each  (--) indicates a  single egg passage. 
11 N: new series of vaccinated mice. 
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gous  (Berkeley-I/53)  vaccine 3  days previously; the inoculum  consisted  of  Berkeley-i/53 
aUantoic fluid (log 9+). The mice were killed 2 days after the intranasal inoculation (5 days 
after vaccination), at which time the lungs of all three showed extensive consolidation.  2 A 
10 per cent suspension of the infected lungs was used to inoculate the second group of mice 
which had been vaccinated with 0.25 mi. quantities of the formalinized vaccine 5 days pre- 
viously.  Three additional passages  (MV3,  MV4,  MV5)  were  made in  the first series but 
data concerning them are not included in Table I  because the lungs were negative for virus 
by egg infectivity tests. The pooled allantoic fluid from eggs used to test the lung suspen- 
sion of the second mouse passage  (MV2)  was used to begin the new series; four passages 
were made in mice which had been vaccinated only once, and three passages in mice which 
had received two intraperitoneal inoculations of the Berkeley-I/53 formalinized vaccine. 
Broadenexl Spectrum of Immunization.--Hemagglutination-inhibition  tests  with  selected 
antiserums indicated that a  definite change had occurred in the antigenic characteristics of 
the  virus,  but  the change was  evidenced  (Table II)  by hemagglutinating activity which 
was more readily inhibited by the antiserums prepared against 1951  strains than was the 
hemagglutinating activity of the parent strain. It seemed that the shift was in the direction 
of the 1951 strains, which was contrary to the experimental plan to produce variants which 
differed from previously known strains. 
In order to block that apparent direction of variation, the spectrum of immunization was 
broadened by including a  1951  strain in the "immunization" procedure;  thus, passage  11 
was made in mice which had received, intraperitoneaUy, 0.5 ml. of the Berkeley-i/53 vaccine 
and subsequently the same quantity of England-I/51 vaccine. Four passages were made in 
mice which had been vaccinated with those two strains. 
The  virus  titer  had  increased  significantly  during  those  twelve  consecutive  passages 
(Nos. 3  through 14)  in mice of an increasing degree of immunity; the last groups of mice 
had been inoculated with 0.5 ml. quantities of high titer vaccine (log 2.9)  2 weeks or more 
and again a week or more previous to intranasal inoculation. It thus appeared that a variant 
may have emerged,  and it was felt that the immunization spectrum could be broadened 
further. A new strain of virus, Engiand-1/54, which arrived during the course of the experi- 
ments was  included in  the vaccination procedure with the expectation that a  more  "ad- 
vanced" variant might be obtained. Lungs from the mice of the next two passages (MV2- 
M13 and MV2-M14; data not included in Table I) contained no virus. An hypothesis of the 
passage failure was that the inoculum (titer per milliliter, log 5.4)  contained too few parti- 
cles to provide for the chance inclusion of an effective number of variants which possessed 
the innate capacity to survive in the new environment. A  new series was begun by inocu- 
lating aliantoic fluid from eggs which had been used to test the last passage (MV2-M12) of 
the previous series, and which contained a  thousandfold (log 8.5) more egg infectious units 
than had  the MV2-M12  10 per cent  mouse lung suspension; passage again was  made in 
mice which had been vaccinated with pooled formalinized vaccine including the England- 
1/51, Berkeley-i/53, and Engiand-1/54 strains. Virus survived two serial passages but was 
not detected in the lungs of the third passage. Consequently, the aUantoic fluid (log 8.0) from 
eggs used to test the MV2-M12-M2 mouse lung suspension was used as inoculum for the 
first  (MV2-M12-M2-M1)  passage of  the next series; it thus was possible to  establish the 
The  findings support  Sugg's  (10)  interpretation of  his data  that lung lesions depend 
upon the quantity of virus present, and probably are not due to processes usually associated 
with multiplication or  "infection." During the course  of  other  experiments an  occasional 
mouse with "immunity" of a  high degree died within 48 hours after intranasal inoculation 
of high titer allantoic fluid but virus could not be recovered from the completely consoli- 
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variant in mice which had been "hyperimmunized" with the triple vaccine. Passage was con- 
tinued with no difficulty and was discontinued after seven passages of that new series. 
Antigenic Charaa~ristics of the Variants 
Table II shows the  capacity of seven antiserums, each of which had been 
prepared with a different 1950-51 or 1952-53 strain of virus, to inhibit hemag- 
glutination by the passage  virus; the latter consisted of allantoic fluid from 
eggs  which had  been inoculated with  the  respective mouse lung suspension. 
The  data  (Table  II)  indicate  that  there  occurred  two  distinct  and  rather 
abrupt changes which were detectable by the tests employed. 
The first evident change appeared between the second (MV2) and fifth (MV2-M3) pas- 
sages in immunized mice. The exact time of occurrence is not clear, because materials from 
the third (MV2-MI) and fourth  (MV2-M2) passages were not available for tests. However, 
the nature of the change is seemingly incongruous in that the variant showed greater affin- 
ity for antibodies evoked by strains related to the one used to immunize the mice in which 
the virus was passaged, than did the parent strain. 
The second change was more in keeping with what  might have been expected, and oc- 
curred between the eleventh (MV2-M9) and fourteenth (MV2-M12) passages in immunized 
mice; and, again, the exact time is not clear because tests were not made with the eleventh, 
twelfth, and thirteenth passage materials. It should be noted, however, that after the first 
change had  been  observed (MV2-M3), no further  change was  evident  through  passage 
MV2-M8, which was the last passage made in mice vaccinated with only the homologous 
Berkeley-I/53  strain.  Beginning with  MV2-M9 passage, the strain England-I/51 was in- 
cluded in the vaccine. That is, hyperimmunization of the passage mice with the homologous 
strain alone did not effect further evident change, but significant change was observed after 
broadening the spectrum by inclusion of an heterologous strain. 
The second variant (MV2-M12 and subsequent passages, Table II) was characterized by 
hemagglutination which was uninhibited by Kentucky-J01/53(v) antiserum, but still strongly 
inhibited by all six of the remaining antiserums. 
Antigenicity  of the Variants 
Hemagglutinafion-inhibition  tests may be an uurefiable index of  the anti- 
genic structure of the hemagglutinating virus in that such tests may provide 
information only concerning the  surface  areas  (11),  and  those  surface  anti- 
gens may be arranged in a  thin layer so  that they represent an insignificant 
quantitative portion of the total antigen complex. 
Antiserums from RabMts.--In order to obtain more accurate information concerning the 
"total antigen complex" (or, more exactly, the antigens which can be determined by anti- 
bodies evoked in experimental animals) two groups of antiserums were prepared  by vac- 
cinating rabbits,  one group with the MV2-M12-M2 variant, and the other group with the 
MV2-M12-M2-M7 variant. 
In tests with  25 strains  of influenza A virus, from various outbreaks  of influenza, the 
MV2-M12-M2 antiserums  completely  inhibited  hemagglutination  by  only  three  strains 
other than the homologous MV2-M12-M2 strain; those three strains (England-i/54, Stock- 
holm-I/54, and Puerto Rico-301/54) were the most recently isolated of the strains available 
for  tests.  Little or  no inhibition  was  evident  against hemagglutinatiol~ by  the  1950-51 TABLE  H 
H emagglutinating* Capacity of Virus, in Presence of Same Antiserums,  but after Increasing No. 
of Passages in Vaccinated Mice 
Antisennn 
1.  Albany-9/51 .................. 
2.  Engl-1/51 ................... 
3.  Kent-301/53v ................ 
4.  Ohio-1/53 ................... 
5.  N. Y.-1/53 .................. 
6.  Berk-2/53 ................... 
7.  Chile-I/53 .................... 
Passage virus 
(Berk-1/53 
vaccine)  Berk-I/53 
MV2 
2222+00  22222+0 
2222+00  2222200 
2220000  222+000 
22+0000  2220000 
2+O0OOO  2+0OOOO 
2200000  22+0000 
22+0000  222+000 
2222200  2222220  Virus titration ................... 
Passage virus 
Antiserum 
1.  Albany-9/51 ................. 
2.  Engl-1/51 ................... 
3.  Kent-301/53v ................ 
4.  Ohio-1/53 ................... 
5.  N.Y.-I/53 ................... 
6.  Berk-2/53 ................... 
7.  Chile-I/53 .................  .. 
Virus titration ................... 
Antiserum 
1.  Albany-9/51 .................. 
2.  Engl-1/51 .................... 
3.  Kent-301/53v ................. 
4.  Ohio-1/53 .................... 
5.  N.Y.-I/53 .................... 
6.  Berk-2/53 .................... 
7.  Chile-I/53 .................... 
Virus titration ................... 
(Berk-1/53 vaccine) 
MV2-M6  MV2-M8  MV2-M3  MV2-M4 
200000  2+0000 
2O000O  2+00OO 
200000  2+0000 
000000  +00000 
000000  000000 
000000  +OOO0O 
000000  0(~000 



































































* 2, complete agglutination of chicken erythrocytes. 
+, partial hemagglutination. 
0, no hemagglutination. 
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strains,  but  strangely, fairly good inhibition was  evident against  hemagglutination by the 
Berkeley-i/53 strain. 
The antiserums from rabbits vaccinated with the MV2-M12-M2-M7 variant behaved in 
a  manner rather similar to the M'V2-M12-M2  antiserums but completely inhibited hemag- 
glutination by the parent strain (Berkeley-I/53) allantoic fluids. 
Antizerums from Mixe.--In order to determine the efficacy  of the vaccination procedure 
and also to gain some idea of the pattern of circulating antibodies, mice were bled from the 
heart at different time intervals following vaccination with the MV2-M12-M2-M7 variant; 
the  limited  quantities  of  serums,  after  treatment  with  cholera  filtrate,  were  tested  for 
capacity to inhibit hemagglutination.  Pertinent  data are included in Table HI. The anti- 
bodies evoked were rather specific in that  they exerted strong inhibitory effect on hemag- 
TABLE  HI 











Time of bleeding  after 
Ist  vacci-  2nd vacci- 
nation  nation 
days  days 
7  4 
7  4 
10  7 
10  7 
10  7 
10  7 
Hemagglutinati0~ inhibitory* capacity of serums from  mice 
vaccinated  with the variant 
Test strain of virus 

























Virus Titration  2222+0  222220  222222  222222 
* 2, +, 0; complete, partial, or no hemagglutination, respectively. 
:~Homologous,  variant  MV2-M12-M2-M7;  Homologous-M1-M1,  second  passage  of 
variant; parent, Berk-1/53. 
§ i.s., insufficient  serum. 
glutination  by the homologous variant  (MV2-M12-M2-M7)  and  a  closely related  variant 
(MV2-M12-M2-M7-M1-M1),  but  exerted no  inhibitory  capacity  on  hemagglutination  by 
the Engiand-1/51 strain, and little effect on hemagglutination by the parent strain  (Berke- 
ley-I/53). 
DISCUSSION 
The present  data  show  that influenza  virus survived in an  environment 
which  had  been  evoked  by intraperitoneal injection of mice  with vaccines 
which  included  the  strictly homologous  strain,  and  that  survival  was  as- 
sociated  with  the  emergence  of variants  which  differed  antigenically from 
the parent strain; they enhance data of other workers (3, 6, 7) that variation 
(or mutation) occurs among the microbes under the impetus of imposed im- 
munological environments. 
The variants appear not to have been of the P-Q kind (8), although super- T~O~AS  P. ~.AOmT.  287 
ficial  examination  of the data may suggest similarities.  The  test antiserums 
inhibited  hemagglutination  by the variants  to  a  much  greater  extent  than 
hemagglutination  by the parent  virus strain;  that  change may seem to re- 
semble  the  Q-P  variation  which  has  been  associated with  "adaptation"  in 
mice.  However, subsequent passage in the homologous immune environment 
did  not  induce  a  P-Q  change,  although  a  complete  reversal  of  inhibitory 
capacity occurred in the case of one antiserum  (Kentucky-301/53); further- 
more, the variants were characterized by an altered antigenicity and evoked 
in rabbits antibodies in high titer, specific for the variants and for the more 
recently isolated strains of virus. 
The  pattern  of variation  seems to  resemble the  pattern  of naturally  oc- 
curring  influenza  virus variation,  in which variants seem to  be characterized 
by  dominant  antigen  complexes  which  were  not  dominant  in  antecedent 
strains  (4,  5).  The  point  may be significant,  that  the  dominant  antibody- 
evoking  components  of  the  variant  could  be  determined  best  against  the 
homologous  strain  and  against  strains  isolated  subsequent  to  the  time  of 
isolation  of the strain  which  was parent  to the variant;  it seems,  therefore, 
that analyses of antigenic structure which depend upon tests with only strains 
of virus which  were isolated previous to time of isolation of the variant may 
furnish only partial information, and therefore, may be unreliable. 
It is a perplexing  point that the variants had the capacity to survive in the 
imposed immunological  environment, yet, in in vitro tests, were affected more 
readily than the parent strain,  by antiserums specific for the strains of virus 
which evoked the environment.  The data seem to support the concept, sug- 
gested by Isaacs, Depoux, and Fiset (11),  that the structure of the influenza 
virus  includes  a  surface  arrangement,  quite  distinct  from  the  inner  virus 
bulk.  On  the  one  hand,  hemagglutination  by the  variants  was  readily  in- 
hibited by antibodies evoked by the 1950-51 strains; on the other hand, those 
same variant preparations  evoked, in rabbits and mice,  antiserums  which  in 
general  failed  to  inhibit  hemagglutination  by the  1950-51  strains,  although 
the  variant  antiserums  exhibited marked  capacity  to  inhibit  hemagglutina- 
tion by the homologous  (variant)  strain,  and  also by strains  of virus which 
were isolated subsequent to isolation of the parent  strain.  That  seeming  in- 
congruity can  be accounted for by assuming  that  the  dominant,  antibody- 
evoking antigen complexes of the various 1950--51, 1952-53,  and  1954 strains 
of virus employed in the tests, all were included among the thin layer of anti- 
gens which  composed the surface structure of the variant,  but that each was 
quantitatively  insignificant  in  terms  of  total  variant  weight.  Accordingly, 
when the variant preparations were injected into rabbits, the chief antibody 
response was evoked by the quantitatively dominant antigens of the interior 
structure,  which  did  not  include  significant  quantities  of  antigens  which 
characterized the surfaces of the 1950-51  strains. 288  VIRUS IN" r~rUNE ENVIRONMENTS 
From  the  view-point of mechanism  of variation,  two  points  in  the  data 
may be of significance. On the one hand, difficulty was encountered in estab- 
lishing  the  passage  series  whenever  the  immunological  environment  was 
changed.  On  the other hand,  once the series was  established,  multiplication 
of the virus appears to have occurred to the same extent in the vaccinated 
mice as in normal, unvaccinated controls. Those points enhance the opinion 
of Archetti and Horsfall  (6)  that  a  basic  change  in  the  hereditary mecha- 
nism may occur under certain imposed environmental conditions; that view, 
however, does not necessarily demand  acceptance of the  idea  of mutation  3 
in the usual usage of the term. The concept of mutation, doubtless, is attrac- 
tive as an explanation of the appearance of new species, but, the very points 
which  make  it  attractive  from  that  point  of view  render  it  inadequate  to 
explain the  survival of existing species.  Perhaps,  variation may result from 
a  rearrangement  of existing  hereditary elements,  rather  than  from a  basic 
change  in  one or more of the  elements;  such  a  mechanism  would  account 
both  for  continuation  of  the  fundamental  hereditary  characteristics  of  the 
species, and for the appearance of variants under the suddenly imposed con- 
ditions of the present experiments. 
The  artificial  conditions  of  the  experiments,  doubtless,  preclude  conclu- 
sions  concerning propagation of virus under natural  conditions, but  the re- 
sults  indicate rather  clearly that  the  mechanism  of virus  variation may be 
more agile than the mechanism of host "immunity." 
strM-~r~.g¥ AND CONCLUSIONS 
Influenza virus can survive, and  can be propagated in ~mmunological en- 
vironments induced  in  mice  by vaccination with  the  homologous strain  of 
virus: survival was associated with the emergence of variants which differed 
from the parent strain in antigenic characteristics. 
The  data  concerning  hemagglutinating  activity  of  the  variants,  on  the 
one hand, and of the antigenicity, on the other, are compatible with the con- 
cept that the structure of the influenza virus includes a  surface arrangement 
which is distinct from the inner virus bulk. 
The points  (a)  that  propagation  was  accomplished  with  difficulty when- 
ever  the  ~mmunological environment was  altered,  and  (b)  that  once estab- 
lished,  passage  was  continued without dlfficulty, are interpreted to indicate 
that  the mechanism of variation may involve a  rearrangement of the  basic 
hereditary mechanism. 
3  Usage has associated the term rnuJ,  ation with a basic, but ill defined, change in one or 
more of the basic hereditary elements; that is, the mutant  differs from its predecessor in 
the  kind  of hereditary elements present: the usual inference is that the process is a dis- 
continuous escape from a relatively rigid genetic process. It is in that sense that it is used 
in the present paper. T~O~S  P. ~G~L  289 
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